ArticlePediatric nephrology (Berlin, Germany)2009
Growth hormone treatment started in the first year of life in infants with chronic renal failure.
Article in Pediatric nephrology (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Energy and protein requirements for children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.Pediatric nephrology (Berlin, Germany) · 2020Guideline
- Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.Nature reviews. Nephrology · 2019Guideline
- Clinical practice recommendations for the care of infants with stage 5 chronic kidney disease (CKD5).Pediatric nephrology (Berlin, Germany) · 2013Guideline
- Improvement in growth after 1 year of growth hormone therapy in well-nourished infants with growth retardation secondary to chronic renal failure: results of a multicenter, controlled, randomized, open clinical trial.Clinical journal of the American Society of Nephrology : CJASN · 2010Trial
- Growth and Recombinant Human Growth Hormone Use in Children with Congenital Chronic Kidney Disease: A Multicentric Contemporary Study.Hormone research in paediatrics · 2026Article
- End-stage kidney disease in infancy: an educational review.Pediatric nephrology (Berlin, Germany) · 2020Review
- Summary of Expert Opinion on the Management of Children With Chronic Kidney Disease and Growth Failure With Human Growth Hormone.Frontiers in endocrinology · 2020Article
- Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine.Pediatric research · 2017Article
- Growth hormone therapy in children with CKD after more than two decades of practice.Pediatric nephrology (Berlin, Germany) · 2016Review
- Chronic haemodialysis in small children: a retrospective study of the Italian Pediatric Dialysis Registry.Pediatric nephrology (Berlin, Germany) · 2016Article
- Nutrition in infants and very young children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2012Review
- Growth hormone in chronic renal disease.Indian journal of endocrinology and metabolism · 2012Article
- Growth in very young children undergoing chronic peritoneal dialysis.Journal of the American Society of Nephrology : JASN · 2011Article
- Peritoneal dialysis in children with end-stage renal disease.Nature reviews. Nephrology · 2011Review
- Growth and body composition in very young SGA children.Pediatric nephrology (Berlin, Germany) · 2010Review
- Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective.Pediatric nephrology (Berlin, Germany) · 2010Review
- Growth hormone treatment of renal growth failure during infancy and early childhood.Pediatric nephrology (Berlin, Germany) · 2009Article
- Growth hormone treatment of infants with chronic kidney disease: requirement, efficacy, and safety.Pediatric nephrology (Berlin, Germany) · 2009Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infants with chronic renal failure (CRF) are at high risk of experiencing severe growth retardation. We report a study of 12 infants with CRF who have been treated with recombinant human growth hormone (rhGH) since the age of 0.5 +/- 0.3 years. A control group comprised 15 infants with less severe CRF who were being treated during the same period, but who did not receive rhGH. Despite the infants in the rhGH group had more severe renal failure, they grew at least as well as those in the control group and experienced catch-up growth that started earlier and was more sustained; they also gained more weight. Between the age of 0.5 and 2.5 years, the height standard deviation score (HtSDS) improved from -2.0 +/- 1.2 to -0.9 +/- 0.9 in the rhGH group (p < 0.005) and from -1.6 +/- 1.6 to -1.0 +/- 1.9 in the control group (p=non significant, n.s.). The average gain in HtSDS was +1.1 +/- 0.8 in the treated group and +0.6 +/- 1.4 in the control group (p = n.s.). During the same period, the weight SDS improved from -2.2 +/- 0.9 to -0.6 +/- 1.2 (p < 0.005) and from -1.9 +/- 1.2 to -1.3 +/- 1.2 (p=n.s.) in the treatment and control groups, respectively. Nutritional intake was similar in both groups, while parathyroid hormone levels tended to increase, although not significantly, after rhGH treatment (p=n.s.). The results of this pilot study suggest that very early treatment with rhGH in patients with early-onset CRF may improve growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.